You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Combination of Pharmacotherapy With Electroconvulsive Therapy in Prevention of Depressive Relapse: A Pilot Controlled Trial

Yildiz, Ayşegül MD*; Mantar, Atil MD*; Simsek, Selçuk MD*; Onur, Elif MD*; Gökmen, Necati MD†; Fidaner, Hüray MD*†

Journal of ECT:
doi: 10.1097/YCT.0b013e3181c189f7
Original Studies
Abstract

Objective: Relapse rates after electroconvulsive therapy (ECT) remain high with standard treatments. We aimed to test the efficacy of an early administered continuation pharmacotherapy (c-pharm early) strategy in prevention of post-ECT relapse.

Method: A 20-week, randomized, double-blind, placebo-controlled trial. Patients aged 18 to 65 years diagnosed with Diagnostic and Statistical Manual of Mental Disorders major depressive disorder, with or without psychotic features, with initial Montgomery-Åsberg Depression Rating Scale scores higher than 22, underwent 8 bilateral ECT sessions (2 per week). Randomization to c-pharm early, c-pharm late, and placebo groups in 2:2:1, respectively, was performed at the completion of the fourth ECT session. After randomization, subjects in the c-pharm early group were given sertraline at 150 mg/d. Subjects in the c-pharm late group were first given placebo, which was substituted with sertraline at 150 mg/d at the completion of the eight ECT. Relapse was defined as a Montgomery-Åsberg Depression Rating Scale score of 16 or higher.

Results: Seventy-three percent of the patients responded to the given treatment. The relapse rates were 12.5% in the c-pharm early group, 28% in the c-pharm late group, and 67% in the placebo group (P = 0.09). The c-pharm early strategy resulted in significantly lower relapse rates and longer well time compared with the placebo (P = 0.04). When the trend with the initiation of the c-pharm intervention was investigated in the 3 groups with equally spaced trend weights, the time of initiation was found to have a significant effect on the probability of the remaining well (P = 0.03).

Conclusions: Comparative efficacy of c-pharm early and late strategies in providing improved protection against post-ECT relapse of major depressive disorder needs to be further explored.

Author Information

From the Departments of *Psychiatry, and †Anesthesiology, Dokuz Eylül University, Izmir, Turkey.

Received for publication December 7, 2008; accepted May 27, 2009.

Reprints: Ayşegül Yildiz, MD, Seferihisar Cad. No. 6/14 Çamli Villaları Sitesi Çamli Köyü, Güzelbahçe PK. 35310 Izmir, Turkey (e-mail: agul_yildiz@hotmail.com).

†Deceased, August 3, 2002.

This study was supported in part by the independent investigator award from the Pfizer Inc, New York, NY, a research project award from the Spring Symposium, Antalya, Turkey, a research grant from the Dokuz Eylül University, Izmir, Turkey, and an educational grant from the Sanofi-Aventis Group, Istanbul, Turkey, which had no influence on design, conduct, analysis or interpretation of the results. Trial registration: AYOO22. Combination of pharmacotherapy with electroconvulsive therapy in prevention of relapse in major depressive disorder: a randomized, placebo controlled, double-blind study (Trial registration number: ISRCTN-28600786). http://www.controlled-trials.com/ISRCTN28600786/

No study investigator has relevant conflicts of interest.

© 2010 Lippincott Williams & Wilkins, Inc.